Completed PHASE2 INTERVENTIONAL 3-arm NCT01190475

BGS649 Monotherapy in Moderate to Severe Endometriosis Patients

A Randomized, Double-blind, Double-dummy, Placebo-controlled Study of Oral BGS649 Monotherapy Assessing Safety and Tolerability in Patients With Moderate to Severe Endometriosis

Sponsor: Mereo BioPharma

Conditions Endometriosis

Interventions Active treatment with a high dose of BGS649 Active treatment with a low dose of BGS649 Placebo treatment to blind study

Updated 9 times since 2017 Last updated: Oct 5, 2020 Started: Jul 31, 2010 Primary completion: Sep 30, 2011 Completion: Sep 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Endometriosis and is currently completed. Mereo BioPharma leads this study, which shows 9 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Dec 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Dec 2021 [monthly]

Completed PHASE2
Nov 2020 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jun 2018 — Nov 2020 [monthly]

Completed PHASE2
Dec 2017 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Dec 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jul 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Mereo BioPharma
Novartis

Data source: Mereo BioPharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Anaheim, United States